P1072

Safety and Immunogenicity of a Live, Attenuated, Rotavirus Vaccine (ROTATEQTM) In HIV-Infected and Uninfected Children Born To HIV-Infected Mothers

Sponsors: US National Institute of Allergy and Infectious Diseases (NIAID)
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Protocol Summary: P1072 is a phase II, randomized, double-blind, placebo controlled trial that is evaluating the safety of any dose of RotaTeq™ given to HIV-1 infected children born to HIV-1 infected mothers and the immunogenicity of a 3-dose regimen of RotaTeq™ in HIV-1 infected and uninfected children born to HIV-1 infected mothers, as measured by serum anti-rotavirus IgA ELISA and serum neutralizing antibody [SNA] responses to serotypes G1, G2, G3, G4, and P1A[8].

Years: 2010 – 2014

Investigator: Mutsawashe Bwakura-Dangarembizi, MBChB, MMED, MSc Cli.Epi

Location: Parirenyatwa CRS

IMPAACT

Completed Study

Publication:

Comments are closed.

Website by Canton Becker